Amanote Research

Amanote Research

    RegisterSign In

Tildrakizumab for the Treatment of Plaque Psoriasis in Adults

Prescriber - United Kingdom
doi 10.1002/psb.1771
Full Text
Open PDF
Abstract

Available in full text

Categories
Pharmacology
Date

June 1, 2019

Authors
Steve Chaplin
Publisher

Wiley


Related search

Risankizumab for the Treatment of Plaque Psoriasis in Adults

Prescriber
Pharmacology
2019English

Infliximab for the Treatment of Plaque Psoriasis

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2008English

Tildrakizumab in the Treatment of Psoriasis: Latest Evidence and Place in Therapy

Therapeutic Advances in Chronic Disease
Medicine
2019English

Dimethyl Fumarate for the Treatment of Plaque Psoriasis

Prescriber
Pharmacology
2018English

Monoclonal Antibodies for the Treatment of Plaque Psoriasis

Prescriber
Pharmacology
2019English

From the Medical Board of the National Psoriasis Foundation: Treatment Targets for Plaque Psoriasis

Journal of the American Academy of Dermatology
Dermatology
2017English

Infliximab for the Treatment of Adults With Psoriasis

Health Technology Assessment
MedicineHealth Policy
2009English

Effectiveness and Safety of Targeted Drugs for the Treatment of Adults With Moderate-To-Severe Plaque Psoriasis in the Russian Federation

Medical Technologies. Assessment and Choice (Медицинские технологии. Оценка и выбор)
2019English

The Development of Practice Guidelines for the Treatment of Severe Plaque Form Psoriasis

Archives of Dermatology
1998English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy